(VIANEWS) – Vaalco Energy (EGY), Corcept Therapeutics Incorporated (CORT), Exelixis (EXEL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Vaalco Energy (EGY)
55.9% sales growth and 11.05% return on equity
VAALCO Energy, Inc., an independent energy company, acquires, explores for, develops, and produces crude oil and natural gas. The company holds Etame production sharing contract related to the Etame Marin block located offshore in the Republic of Gabon, West Africa. It also owns interests in an undeveloped block offshore Equatorial Guinea, West Africa. VAALCO Energy, Inc. was founded in 1985 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Vaalco Energy has a trailing twelve months EPS of $0.31.
PE Ratio
Vaalco Energy has a trailing twelve months price to earnings ratio of 13.55. Meaning, the purchaser of the share is investing $13.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.05%.
2. Corcept Therapeutics Incorporated (CORT)
19% sales growth and 21.9% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.81.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 34.68. Meaning, the purchaser of the share is investing $34.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.9%.
3. Exelixis (EXEL)
16.2% sales growth and 3.8% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.5.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 40.26. Meaning, the purchaser of the share is investing $40.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 2.47%.
4. Cinemark Holdings (CNK)
14.8% sales growth and 40.81% return on equity
Cinemark Holdings, Inc., together with its subsidiaries, engages in the motion picture exhibition business. As of October 8, 2021, it operated 521 theatres with 5,864 screens in the United States, and South and Central America. The company was founded in 1984 and is headquartered in Plano, Texas.
Earnings Per Share
As for profitability, Cinemark Holdings has a trailing twelve months EPS of $0.6.
PE Ratio
Cinemark Holdings has a trailing twelve months price to earnings ratio of 24.08. Meaning, the purchaser of the share is investing $24.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.81%.
Yearly Top and Bottom Value
Cinemark Holdings’s stock is valued at $14.45 at 04:22 EST, way under its 52-week high of $19.85 and way above its 52-week low of $8.28.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 93.9% and 300%, respectively.
Sales Growth
Cinemark Holdings’s sales growth is 8.9% for the current quarter and 14.8% for the next.
Moving Average
Cinemark Holdings’s value is way below its 50-day moving average of $16.88 and below its 200-day moving average of $15.83.
5. Synergetics USA (SURG)
10.8% sales growth and 130.07% return on equity
SurgePays, Inc., through its subsidiaries, provides telecommunication services in the United States. It offers discounted and free wireless services for federal programs, such as SNAP (EBT) and Medicaid; subsidized wireless service to qualifying low income customers; repaid wireless plans with talk, text, and 4G LTE data; and client acquisition and retention services for attorneys and law firms by operating digital marketing campaigns. The company also provides financial technology tech and wireless top-up platform; and SurgePays Blockchain software, an e-commerce platform, which offer wholesale goods and services direct to convenience stores, bodegas, minimarts, tiendas, and other corner stores. In addition, it provides sales support, customer, IT infrastructure design, graphic media, database programming, software development, revenue assurance, lead generation, call center support, and other services. The company was formerly known as Surge Holdings, Inc. and changed its name to SurgePays, Inc. in November 2020. SurgePays, Inc. is headquartered in Bartlett, Tennessee.
Earnings Per Share
As for profitability, Synergetics USA has a trailing twelve months EPS of $0.84.
PE Ratio
Synergetics USA has a trailing twelve months price to earnings ratio of 5.73. Meaning, the purchaser of the share is investing $5.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 130.07%.
Moving Average
Synergetics USA’s worth is above its 50-day moving average of $4.68 and way below its 200-day moving average of $5.35.
Sales Growth
Synergetics USA’s sales growth is 13.5% for the present quarter and 10.8% for the next.
Volume
Today’s last reported volume for Synergetics USA is 146126 which is 35.64% above its average volume of 107729.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Synergetics USA’s EBITDA is 15.78.
6. Eagle Point Credit Company (ECC)
9.4% sales growth and 8.66% return on equity
Eagle Point Credit Company Inc. is a closed ended fund launched and managed by Eagle Point Credit Management LLC. It invests in fixed income markets of the United States. The fund invests equity and junior debt tranches of collateralized loan obligations consisting primarily of below investment grade U.S. senior secured loans. Eagle Point Credit Company Inc. was formed on March 24, 2014 and is domiciled in the United States.
Earnings Per Share
As for profitability, Eagle Point Credit Company has a trailing twelve months EPS of $1.09.
PE Ratio
Eagle Point Credit Company has a trailing twelve months price to earnings ratio of 8.74. Meaning, the purchaser of the share is investing $8.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.66%.
Sales Growth
Eagle Point Credit Company’s sales growth is 10.6% for the ongoing quarter and 9.4% for the next.
Moving Average
Eagle Point Credit Company’s value is below its 50-day moving average of $9.80 and under its 200-day moving average of $10.50.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 7, 2023, the estimated forward annual dividend rate is 1.68 and the estimated forward annual dividend yield is 17.78%.
7. Incyte Corporation (INCY)
9.2% sales growth and 9.28% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 28.7. Meaning, the purchaser of the share is investing $28.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 70% and 95.2%, respectively.
8. Armada Hoffler Properties (AHH)
9.1% sales growth and 4.87% return on equity
Armada Hoffler Properties, Inc. (NYSE: AHH) is a vertically-integrated, self-managed real estate investment trust ("REIT") with four decades of experience developing, building, acquiring, and managing high-quality, institutional-grade office, retail, and multifamily properties located primarily in the Mid-Atlantic and Southeastern United States. In addition to developing and building properties for its own account, the Company also provides development and general contracting construction services to third-party clients. Founded in 1979 by Daniel A. Hoffler, the Company has elected to be taxed as a REIT for U.S. federal income tax purposes.
Earnings Per Share
As for profitability, Armada Hoffler Properties has a trailing twelve months EPS of $0.35.
PE Ratio
Armada Hoffler Properties has a trailing twelve months price to earnings ratio of 29.37. Meaning, the purchaser of the share is investing $29.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.87%.
